A	O
randomized	O
two	O
way	O
cross	O
over	O
study	O
for	O
comparison	O
of	O
absorption	O
of	O
vitamin	O
D3	O
buccal	O
spray	O
and	O
soft	O
gelatin	O
capsule	O
formulation	O
in	O
healthy	O
subjects	O
and	O
in	O
patients	O
with	O
intestinal	O
malabsorption	O

Background	O

Vitamin	B-DS
D	I-DS
deficiency	I-DS
has	O
been	O
proposed	O
to	O
contribute	O
to	O
the	O
development	O
of	O
malabsorption	O
diseases	O
.	O

Despite	O
this	O
,	O
the	O
vitamin	O
D	O
status	O
of	O
these	O
patients	O
is	O
often	O
neglected	O
.	O

The	O
objective	O
of	O
the	O
present	O
work	O
was	O
to	O
compare	O
the	O
absorption	O
of	O
vitamin	O
D3	O
through	O
the	O
oral	O
route	O
by	O
comparing	O
a	O
1000	O
IU	O
soft	O
gelatin	O
capsule	O
and	O
a	O
500	O
IU	O
buccal	O
spray	O
(	O
delivering	O
1000	O
IU	O
in	O
two	O
spray	O
shots	O
)	O
in	O
healthy	O
subjects	O
and	O
in	O
patients	O
with	O
malabsorption	B-DS
disease	I-DS
.	O

Methods	O

An	O
open	O
label	O
,	O
randomized	O
,	O
two	O
-	O
periods	O
,	O
two	O
-	O
way	O
cross	O
over	O
study	O
was	O
conducted	O
,	O
first	O
in	O
healthy	O
subjects	O
(	O
n	O
=	O
20	O
)	O
and	O
then	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
(	O
n	O
=	O
20	O
).	O

The	O
study	O
participants	O
were	O
equally	O
divided	O
and	O
received	O
either	O
of	O
the	O
treatments	O
(	O
buccal	O
spray	O
,	O
n	O
=	O
7	O
;	O
soft	O
gelatin	O
capsule	O
,	O
n	O
=	O
7	O
;	O
control	O
,	O
n	O
=	O
6	O
)	O
in	O
Period	O
I	O
for	O
30	O
days	O
.	O

After	O
washout	O
of	O
another	O
30	O
days	O
,	O
the	O
treatments	O
were	O
changed	O
in	O
crossover	O
fashion	O
in	O
Period	O
II	O
.	O

Fasting	O
blood	O
samples	O
were	O
collected	O
to	O
measure	O
baseline	O
25	O
-	O
hydroxyvitamin	O
D	O
[	O
25	O
(	O
OH	O
)	O
D	O
]	O
levels	O
in	O
all	O
participants	O
at	O
day	O
0	O
(	O
Screening	O
visit	O
),	O
day	O
30	O
(	O
completion	O
of	O
period	O
I	O
),	O
day	O
60	O
(	O
end	O
of	O
wash	O
out	O
and	O
initiation	O
of	O
period	O
II	O
)	O
and	O
day	O
90	O
(	O
completion	O
of	O
period	O
II	O
).	O

Safety	O
was	O
evaluated	O
by	O
hematology	O
and	O
biochemistry	O
analyses	O
.	O

Statistical	O
analyses	O
was	O
performed	O
using	O
differences	O
of	O
mean	O
and	O
percentage	O
change	O
from	O
baseline	O
of	O
25	O
(	O
OH	O
)	O
D	O
levels	O
between	O
two	O
formulation	O
by	O
two	O
tailed	O
Paired	O
t	O
-	O
test	O
with	O
95	O
%	O
confidence	O
interval	O
.	O

Results	O

In	O
healthy	O
subjects	O
,	O
the	O
mean	O
increase	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
4	O
.	O
06	O
(	O
95	O
%	O
CI	O
3	O
.	O
41	O
,	O
4	O
.	O
71	O
)	O
ng	O
/	O
ml	O
in	O
soft	O
gelatin	O
capsule	O
group	O
and	O
8	O
.	O
0	O
(	O
95	O
%	O
CI	O
6	O
.	O
86	O
,	O
9	O
.	O
13	O
)	O
ng	O
/	O
ml	O
in	O
buccal	O
spray	O
group	O
after	O
30	O
days	O
treatment	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

In	O
patients	O
with	O
malabsorption	B-DS
disease	I-DS
,	O
the	O
mean	O
increase	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
3	O
.	O
96	O
(	O
95	O
%	O
CI	O
2	O
.	O
37	O
,	O
5	O
.	O
56	O
)	O
ng	O
/	O
ml	O
in	O
soft	O
gelatin	O
capsule	O
group	O
and	O
10	O
.	O
46	O
(	O
95	O
%	O
CI	O
6	O
.	O
89	O
,	O
14	O
.	O
03	O
)	O
ng	O
/	O
ml	O
in	O
buccal	O
spray	O
group	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

Conclusion	O

It	O
can	O
be	O
concluded	O
from	O
the	O
results	O
that	O
the	O
buccal	O
spray	O
produced	O
a	O
significantly	O
higher	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
as	O
compared	O
to	O
the	O
soft	O
gelatin	O
capsule	O
,	O
in	O
both	O
healthy	O
subjects	O
as	O
well	O
as	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
over	O
a	O
period	O
of	O
30	O
days	O
administration	O
in	O
a	O
two	O
way	O
cross	O
over	O
study	O
.	O

Treatments	O
were	O
well	O
tolerated	O
by	O
both	O
subject	O
groups	O

Trial	O
Registration	O

CTRI	O
/	O
2013	O
/	O
06	O
/	O
003770	O

Introduction	O

Vitamin	O
D	O
is	O
essential	O
for	O
active	O
intestinal	O
calcium	O
absorption	O
and	O
plays	O
a	O
central	O
role	O
in	O
maintaining	O
calcium	O
homeostasis	O
and	O
skeletal	O
integrity	O
.	O

It	O
is	O
derived	O
mainly	O
from	O
cutaneous	O
synthesis	O
in	O
the	O
presence	O
of	O
ultraviolet	O
sunlight	O
while	O
dietary	O
intake	O
constitutes	O
a	O
minor	O
fraction	O
[	O
1	O
].	O

Vitamin	B-DS
D	I-DS
deficiency	I-DS
is	O
a	O
common	O
problem	O
through	O
the	O
world	O
[	O
2	O
,	O
3	O
]	O
and	O
is	O
assessed	O
by	O
low	O
serum	O
concentration	O
of	O
the	O
major	O
circulating	O
metabolite	O
25	O
-	O
hydroxyvitamin	O
D	O
(	O
25	O
(	O
OH	O
)	O
D	O
)	O
[	O
4	O
,	O
5	O
].	O

The	O
prevention	O
of	O
vitamin	B-DS
D	I-DS
deficiency	I-DS
and	O
insufficiency	O
remains	O
a	O
priority	O
of	O
international	O
health	O
services	O
[	O
6	O
â€“	O
8	O
].	O

Vitamin	B-DS
D	I-DS
deficiency	I-DS
has	O
been	O
proposed	O
to	O
contribute	O
to	O
the	O
development	O
of	O
intestinal	B-DS
bowel	I-DS
diseases	I-DS
like	O
Crohn	B-DS
'	I-DS
s	I-DS
disease	I-DS
,	O
steatorrhea	O
and	O
ulcerative	B-DS
colitis	I-DS
[	O
9	O
].	O

Conversely	O
,	O
people	O
who	O
have	O
such	O
illnesses	O
have	O
a	O
reduced	O
absorption	O
of	O
vitamin	O
D3	O
through	O
the	O
intestine	O
[	O
10	O
,	O
11	O
].	O

In	O
addition	O
,	O
osteomalacia	B-DS
occurs	O
in	O
patients	O
with	O
a	O
wide	O
variety	O
of	O
disorders	O
affecting	O
the	O
stomach	O
and	O
small	O
bowel	O
,	O
especially	O
when	O
associated	O
with	O
steatorrhea	O
.	O

The	O
pathogenesis	O
of	O
this	O
osteomalacia	B-DS
has	O
in	O
part	O
been	O
explained	O
by	O
malabsorption	O
in	O
vitamin	O
D	O
[	O
9	O
].	O

Earlier	O
reports	O
show	O
that	O
orally	O
administered	O
tritiated	O
vitamin	O
D3	O
was	O
malabsorbed	O
in	O
patients	O
with	O
celiac	B-DS
disease	I-DS
,	O
biliary	B-DS
obstruction	I-DS
or	O
pancreatic	B-DS
disease	I-DS
[	O
12	O
].	O

The	O
pathogenesis	O
of	O
vitamin	B-DS
D	I-DS
deficiency	I-DS
in	O
these	O
patients	O
remains	O
unclear	O
but	O
it	O
is	O
thought	O
to	O
result	O
primarily	O
from	O
fat	O
soluble	O
vitamin	O
malabsorption	O
due	O
to	O
the	O
presence	O
of	O
intestinal	B-DS
disease	I-DS
conditions	O

Despite	O
vitamin	O
D	O
malabsorption	O
in	O
patients	O
with	O
gastrointestinal	O
or	O
liver	B-DS
disease	I-DS
,	O
the	O
vitamin	O
status	O
of	O
these	O
patients	O
is	O
often	O
neglected	O
.	O

Although	O
vitamin	O
D	O
supplements	O
are	O
often	O
prescribed	O
,	O
adequate	O
absorption	O
of	O
these	O
formulations	O
has	O
not	O
been	O
documented	O
[	O
10	O
].	O

Vitamin	O
D	O
is	O
known	O
to	O
be	O
liposoluble	O
,	O
and	O
its	O
relative	O
bioavailability	O
could	O
result	O
in	O
unfavorable	O
conditions	O
when	O
administered	O
in	O
solid	O
form	O
(	O
capsule	O
),	O
since	O
the	O
process	O
of	O
its	O
release	O
is	O
a	O
factor	O
limiting	O
the	O
rate	O
of	O
absorption	O
,	O
bearing	O
in	O
mind	O
that	O
bioavailability	O
is	O
related	O
not	O
only	O
to	O
the	O
pharmaceutically	O
active	O
molecules	O
,	O
but	O
also	O
,	O
to	O
the	O
formulation	O
and	O
excipients	O
used	O
.	O

Vitamin	O
D3	O
taken	O
by	O
oral	O
route	O
(	O
peroral	O
delivery	O
)	O
is	O
absorbed	O
in	O
the	O
intestine	O
,	O
where	O
the	O
lining	O
of	O
the	O
digestive	O
tract	O
is	O
aqueous	O
in	O
nature	O
.	O

Therefore	O
vitamin	O
D3	O
,	O
a	O
fat	O
-	O
soluble	O
molecule	O
,	O
in	O
order	O
to	O
be	O
absorbed	O
,	O
must	O
be	O
made	O
water	O
soluble	O
in	O
the	O
intestine	O
.	O

This	O
is	O
accomplished	O
in	O
two	O
steps	O
:	O
emulsification	O
of	O
vitamin	O
D3	O
in	O
the	O
intestinal	O
lumen	O
,	O
through	O
the	O
action	O
of	O
bile	O
salts	O
,	O
forming	O
small	O
droplets	O
which	O
are	O
dispersed	O
and	O
incorporated	O
into	O
micelles	O
-	O
complex	O
aggregates	O
formed	O
by	O
the	O
interaction	O
of	O
free	O
fatty	O
acids	O
,	O
monoglycerides	O
,	O
and	O
bile	O
salts	O
.	O

Micelles	O
are	O
sufficiently	O
water	O
-	O
soluble	O
to	O
access	O
the	O
intestinal	O
brush	O
border	O
where	O
upon	O
the	O
vitamin	O
D3	O
content	O
is	O
released	O
and	O
then	O
absorbed	O
[	O
13	O
].	O

When	O
sprayed	O
inside	O
the	O
mouth	O
,	O
the	O
fine	O
micro	O
sized	O
droplets	O
of	O
vitamin	O
D3	O
are	O
believed	O
to	O
be	O
quickly	O
and	O
completely	O
absorbed	O
through	O
the	O
buccal	O
mucosa	O
into	O
the	O
numerous	O
capillaries	O
and	O
veins	O
lying	O
close	O
to	O
the	O
tissue	O
surface	O
[	O
13	O
].	O

Considering	O
the	O
possibility	O
of	O
reduced	O
vitamin	O
D	O
absorption	O
in	O
healthy	O
subjects	O
and	O
even	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
,	O
a	O
buccal	O
spray	O
formulation	O
was	O
developed	O
.	O

Therefore	O
,	O
the	O
objective	O
of	O
the	O
present	O
work	O
was	O
to	O
compare	O
the	O
absorption	O
of	O
vitamin	O
D3	O
through	O
the	O
oral	O
route	O
(	O
soft	O
gelatin	O
capsule	O
form	O
)	O
and	O
buccal	O
spray	O
in	O
healthy	O
subjects	O
and	O
patients	O
with	O
intestinal	B-DS
malabsorption	I-DS
syndrome	I-DS
.	O

Methods	O

Study	O
design	O
and	O
patients	O

An	O
open	O
label	O
,	O
randomized	O
,	O
two	O
-	O
periods	O
,	O
two	O
-	O
way	O
cross	O
over	O
study	O
was	O
conducted	O
,	O
first	O
in	O
healthy	O
subjects	O
and	O
then	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
,	O
with	O
a	O
similar	O
study	O
design	O
except	O
the	O
presence	O
of	O
disease	O
status	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
.	O

After	O
approval	O
from	O
the	O
Spandan	O
-	O
IEC	O
ethics	O
committee	O
(	O
registration	O
no	O
:	O
ECR	O
/	O
67	O
/	O
Indt	O
/	O
GJ	O
/	O
2013	O
),	O
the	O
informed	O
consent	O
of	O
study	O
participants	O
were	O
taken	O
and	O
the	O
formulation	O
was	O
administered	O
for	O
30	O
days	O
in	O
period	O
I	O
where	O
half	O
of	O
the	O
subjects	O
and	O
patients	O
(	O
collectively	O
participants	O
)	O
received	O
capsule	O
formulation	O
and	O
half	O
of	O
the	O
participants	O
received	O
buccal	O
spray	O
formulation	O
.	O

After	O
completion	O
of	O
treatment	O
in	O
period	O
I	O
,	O
all	O
participants	O
were	O
given	O
30	O
days	O
wash	O
out	O
before	O
initiating	O
period	O
II	O
where	O
treatment	O
has	O
changed	O
in	O
cross	O
over	O
fashion	O
,	O
i	O
.	O
e	O
.	O
the	O
participants	O
who	O
received	O
capsule	O
formulation	O
in	O
period	O
I	O
have	O
received	O
buccal	O
spray	O
in	O
period	O
II	O
and	O
vice	O
versa	O
.	O

The	O
clinical	O
study	O
was	O
registered	O
in	O
a	O
centralized	O
clinical	O
trial	O
registry	O
of	O
India	O
(	O
CTRI	O
)	O
before	O
initiating	O
the	O
enrollment	O
of	O
the	O
first	O
patient	O
in	O
the	O
study	O
(	O
CTRI	O
/	O
2013	O
/	O
06	O
/	O
003770	O
).	O

The	O
inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
subjects	O
of	O
either	O
sex	O
between	O
18	O
and	O
65	O
years	O
of	O
age	O
,	O
with	O
a	O
Body	O
Mass	O
Index	O
(	O
BMI	O
)	O
between	O
18	O
.	O
0	O
and	O
30	O
.	O
0	O
kg	O
/	O
m2	O
,	O
and	O
the	O
ability	O
to	O
comply	O
with	O
study	O
procedures	O
in	O
the	O
opinion	O
of	O
the	O
investigators	O
.	O

For	O
healthy	O
subjects	O
:	O
no	O
history	O
of	O
liver	O
,	O
kidney	O
or	O
cardiovascular	B-DS
disease	I-DS
,	O
or	O
of	O
any	O
other	O
medical	O
conditions	O
or	O
medications	O
likely	O
to	O
affect	O
vitamin	O
D3	O
absorption	O
or	O
metabolism	O
.	O

For	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
:	O
confirmed	O
diagnosis	O
of	O
any	O
one	O
of	O
the	O
following	O
malabsorption	B-DS
disease	I-DS
conditions	O
like	O
ulcerative	B-DS
colitis	I-DS
,	O
Crohn	B-DS
â€™	I-DS
s	I-DS
disease	I-DS
or	O
steatorrhea	O
.	O

Patient	O
with	O
history	O
of	O
above	O
diseases	O
,	O
who	O
are	O
on	O
therapy	O
,	O
were	O
selected	O
for	O
the	O
screening	O
.	O

In	O
these	O
patients	O
,	O
malabsorption	B-DS
syndrome	I-DS
was	O
diagnosed	O
by	O
clinical	O
symptoms	O
like	O
abdominal	O
pain	O
,	O
vomiting	O
,	O
diarrhea	O
,	O
and	O
subcutaneous	O
fat	O
loss	O
together	O
with	O
blood	O
tests	O
like	O
haematology	O
and	O
biochemistry	O
.	O

Stool	O
examination	O
was	O
also	O
performed	O
for	O
all	O
patients	O
to	O
confirm	O
rectal	O
bleeding	O
,	O
presence	O
of	O
occult	O
blood	O
,	O
infectious	O
organisms	O
,	O
or	O
fat	O
.	O

Finally	O
,	O
colonoscopy	O
was	O
performed	O
in	O
all	O
patients	O
to	O
objectively	O
assess	O
the	O
extent	O
of	O
inflammation	O
to	O
confirm	O
the	O
diagnosis	O
.	O

The	O
exclusion	O
criteria	O
were	O
as	O
follows	O
:	O
systemic	O
inflammatory	O
or	O
malignant	O
disease	O
;	O
hepatic	O
or	O
renal	B-DS
failure	I-DS
;	O
uncontrolled	O
hypo	O
-	O
or	O
hyperthyroidism	B-DS
,	O
or	O
the	O
use	O
of	O
drugs	O
that	O
are	O
known	O
to	O
affect	O
bone	O
metabolism	O
such	O
as	O
bisphosphonates	O
,	O
glucocorticoids	O
and	O
anti	O
-	O
convulsants	O
.	O

A	O
pregnant	O
or	O
desired	O
to	O
be	O
pregnant	O
woman	O
during	O
study	O
period	O
was	O
also	O
excluded	O
.	O

Data	O
collected	O
at	O
baseline	O

Each	O
participant	O
completed	O
a	O
self	O
-	O
administered	O
questionnaire	O
before	O
enrollment	O
.	O

During	O
completion	O
of	O
the	O
questionnaire	O
,	O
they	O
had	O
the	O
possibility	O
to	O
ask	O
for	O
assistance	O
(	O
i	O
.	O
e	O
.	O
clarification	O
of	O
question	O
or	O
any	O
other	O
issue	O
)	O
from	O
one	O
of	O
the	O
project	O
leaders	O
.	O

The	O
questionnaire	O
included	O
questions	O
about	O
usual	O
intake	O
of	O
vitamin	O
D	O
containing	O
foods	O
,	O
clothing	O
and	O
sun	O
exposure	O
habits	O
,	O
as	O
well	O
as	O
height	O
&	O
weight	O
,	O
date	O
of	O
birth	O
,	O
and	O
education	O
.	O

Body	O
mass	O
index	O
was	O
derived	O
as	O
wt	O
/	O
ht2	O
(	O
kg	O
/	O
m2	O
).	O

Blood	O
pressure	O
was	O
measured	O
through	O
sphygmomanometer	O
and	O
vitals	O
(	O
heart	O
rate	O
,	O
body	O
temperature	O
)	O
were	O
also	O
recorded	O
for	O
safety	O
purposes	O
.	O

Collection	O
and	O
analyses	O
of	O
blood	O
samples	O

Fasting	O
blood	O
samples	O
were	O
collected	O
to	O
measure	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
levels	O
in	O
all	O
the	O
participants	O
at	O
day	O
0	O
(	O
Screening	O
visit	O
),	O
day	O
30	O
(	O
completion	O
of	O
period	O
I	O
),	O
day	O
60	O
(	O
end	O
of	O
wash	O
out	O
and	O
initiation	O
of	O
period	O
II	O
)	O
and	O
day	O
90	O
(	O
completion	O
of	O
period	O
II	O
).	O

Blood	O
samples	O
were	O
centrifuged	O
(	O
15	O
min	O
;	O
2000	O
g	O
at	O
4	O
Â°	O
C	O
)	O
within	O
30	O
min	O
of	O
blood	O
collection	O
and	O
separated	O
serum	O
samples	O
were	O
immediately	O
frozen	O
.	O

Serum	O
samples	O
were	O
stored	O
at	O
âˆ’	O
20	O
Â°	O
C	O
until	O
analyzed	O
.	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
levels	O
were	O
measured	O
by	O
Electrochemiluminescence	O
(	O
ECLIA	O
)	O
assay	O
method	O
.	O

This	O
assay	O
was	O
carried	O
out	O
through	O
quantitative	O
determinations	O
of	O
total	O
25	O
-	O
hydroxyvitamin	O
D	O
in	O
serum	O
samples	O
using	O
a	O
standard	O
kit	O
available	O
from	O
Roche	O
diagnostics	O
GmbH	O
,	O
Germany	O
.	O

All	O
analyses	O
were	O
done	O
in	O
a	O
central	O
independent	O
clinical	O
analysis	O
laboratory	O
(	O
APL	O
Institute	O
of	O
Clinical	O
Laboratory	O
&	O
Research	O
Pvt	O
.	O

Ltd	O
.,	O
Ahmedabad	O
,	O
India	O
).	O

The	O
kit	O
has	O
a	O
limit	O
of	O
detection	O
of	O
3	O
ng	O
/	O
mL	O
and	O
has	O
a	O
linearity	O
of	O
0	O
.	O
0	O
to	O
60	O
.	O
0	O
ng	O
/	O
mL	O
.	O

The	O
intra	O
-	O
assay	O
and	O
inter	O
-	O
assay	O
co	O
-	O
efficient	O
of	O
variation	O
were	O
4	O
%	O
and	O
6	O
%,	O
respectively	O
.	O

Elecsys	O
e	O
-	O
immunoassay	O
analyzers	O
were	O
used	O
for	O
this	O
assay	O
.	O

Safety	O
parameters	O
were	O
evaluated	O
including	O
hematology	O
analyses	O
(	O
complete	O
blood	O
counts	O
),	O
biochemical	O
analyses	O
(	O
serum	O
creatinine	O
,	O
total	O
bilirubin	O
,	O
urea	O
,	O
SGOT	B-GP
,	O
SGPT	B-GP
,	O
alkaline	O
phosphates	O
,	O
calcium	O
)	O
and	O
urine	O
was	O
collected	O
for	O
urine	O
routine	O
and	O
microbiological	O
analyses	O
at	O
screening	O
visit	O
(	O
day	O
0	O
)	O
and	O
at	O
the	O
end	O
of	O
period	O
II	O
visit	O
(	O
day	O
90	O
).	O

Intervention	O
randomization	O
and	O
compliance	O

Randomization	O
and	O
group	O
allocation	O
:	O

The	O
participants	O
were	O
enrolled	O
at	O
two	O
different	O
hospital	O
sites	O
in	O
India	O
;	O
one	O
physician	O
â€™	O
s	O
site	O
where	O
all	O
healthy	O
subjects	O
were	O
recruited	O
and	O
a	O
gastroenterologist	O
â€™	O
s	O
site	O
where	O
all	O
patients	O
with	O
intestinal	O
malabsorption	O
were	O
recruited	O
.	O

Out	O
of	O
the	O
forty	O
-	O
eight	O
participants	O
who	O
met	O
the	O
eligibility	O
criteria	O
,	O
forty	O
(	O
twenty	O
healthy	O
and	O
twenty	O
patients	O
)	O
had	O
agreed	O
to	O
participate	O
and	O
were	O
found	O
eligible	O
,	O
signed	O
a	O
written	O
consent	O
form	O
,	O
and	O
completed	O
a	O
self	O
administered	O
questionnaire	O
concerning	O
usual	O
diet	O
and	O
sun	O
exposure	O
.	O

Subsequently	O
,	O
a	O
venous	O
blood	O
sample	O
was	O
drawn	O
,	O
and	O
a	O
participant	O
received	O
a	O
sealed	O
,	O
non	O
-	O
transparent	O
envelope	O
with	O
the	O
allocated	O
treatment	O
intervention	O
.	O

The	O
randomization	O
procedure	O
was	O
performed	O
beforehand	O
by	O
a	O
statistician	O
by	O
block	O
randomization	O
with	O
blocks	O
of	O
two	O
to	O
one	O
ratio	O
,	O
where	O
the	O
first	O
two	O
participants	O
were	O
randomly	O
given	O
each	O
treatment	O
and	O
a	O
third	O
participant	O
served	O
as	O
a	O
control	O
and	O
didn	O
â€™	O
t	O
receive	O
any	O
treatment	O
.	O

The	O
participants	O
were	O
allocated	O
to	O
the	O
interventions	O
as	O
they	O
visited	O
the	O
clinic	O
i	O
.	O
e	O
.	O
the	O
first	O
subject	O
was	O
allocated	O
to	O
buccal	O
spray	O
group	O
,	O
second	O
to	O
soft	O
gelatin	O
capsule	O
group	O
and	O
third	O
to	O
the	O
control	O
group	O
.	O

This	O
was	O
done	O
in	O
order	O
to	O
distribute	O
the	O
participants	O
equally	O
in	O
the	O
two	O
interventions	O
(	O
Group	O
I	O
and	O
Group	O
III	O
)	O
and	O
half	O
of	O
the	O
participants	O
served	O
as	O
a	O
control	O
(	O
Group	O
II	O
and	O
Group	O
IV	O
).	O

Twenty	O
healthy	O
subjects	O
enrolled	O
for	O
the	O
study	O
were	O
recruited	O
at	O
a	O
physician	O
â€™	O
s	O
site	O
.	O

They	O
were	O
randomized	O
and	O
enrolled	O
into	O
group	O
I	O
and	O
II	O
:	O
fourteen	O
subjects	O
were	O
enrolled	O
for	O
vitamin	O
D3	O
treatment	O
and	O
labeled	O
as	O
group	O
I	O
(	O
healthy	O
subjects	O
),	O
while	O
every	O
third	O
subject	O
(	O
total	O
six	O
subjects	O
)	O
were	O
not	O
given	O
any	O
treatment	O
(	O
labeled	O
as	O
group	O
II	O
)	O
and	O
acted	O
as	O
the	O
control	O
for	O
group	O
I	O
.	O

The	O
twenty	O
patients	O
with	O
confirmed	O
diagnosis	O
of	O
malabsorption	B-DS
syndromes	I-DS
(	O
nine	O
with	O
ulcerative	B-DS
colitis	I-DS
,	O
four	O
with	O
Crohn	B-DS
â€™	I-DS
s	I-DS
disease	I-DS
and	O
seven	O
with	O
steatorrhea	O
)	O
were	O
recruited	O
at	O
a	O
gastroenterologist	O
â€™	O
s	O
hospital	O
site	O
.	O

Fourteen	O
subjects	O
were	O
enrolled	O
for	O
vitamin	O
D3	O
treatment	O
and	O
labeled	O
as	O
group	O
III	O
(	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
),	O
while	O
every	O
third	O
subject	O
(	O
total	O
six	O
subjects	O
)	O
were	O
not	O
given	O
any	O
treatment	O
(	O
labeled	O
as	O
group	O
IV	O
)	O
and	O
acted	O
as	O
the	O
control	O
for	O
group	O
III	O
.	O

All	O
patients	O
continued	O
to	O
take	O
their	O
treatment	O
for	O
ulcerative	B-DS
colitis	I-DS
,	O
Crohn	B-DS
â€™	I-DS
s	I-DS
disease	I-DS
and	O
steatorrhea	O
as	O
prescribed	O
by	O
gastroenterologists	O
.	O

Treatment	O
allocation	O
was	O
assigned	O
to	O
each	O
participant	O
according	O
to	O
their	O
number	O
of	O
sequence	O
of	O
attendance	O
at	O
the	O
blood	O
sampling	O
.	O

Treatment	O
allocation	O
was	O
concealed	O
in	O
envelopes	O
numbered	O
in	O
ascending	O
order	O
that	O
they	O
met	O
.	O

Study	O
personnel	O
involved	O
in	O
recruitment	O
and	O
data	O
collection	O
were	O
blinded	O
to	O
the	O
participant	O
â€™	O
s	O
treatment	O
allocation	O
.	O

All	O
participants	O
were	O
instructed	O
to	O
maintain	O
their	O
routine	O
lifestyle	O
including	O
diet	O
habits	O
and	O
sun	O
exposure	O
during	O
the	O
entire	O
study	O
period	O
,	O
to	O
minimize	O
interference	O
with	O
the	O
daily	O
routine	O
.	O

Intervention	O

The	O
buccal	O
spray	O
and	O
soft	O
gelatin	O
capsules	O
containing	O
vitamin	O
D3	O
were	O
supplied	O
by	O
Pharma	O
Base	O
,	O
India	O
(	O
a	O
subsidiary	O
of	O
Pharma	O
Base	O
SA	O
,	O
Switzerland	O
).	O

The	O
soft	O
gelatin	O
capsule	O
formulation	O
was	O
purchased	O
from	O
the	O
Indian	O
market	O
.	O

The	O
analysis	O
of	O
both	O
the	O
formulations	O
was	O
done	O
in	O
triplicate	O
according	O
to	O
the	O
method	O
described	O
in	O
European	O
Pharmacopeia	O
at	O
an	O
independent	O
analytical	O
laboratory	O
(	O
Oasis	O
Testing	O
House	O
,	O
Ahmedabad	O
,	O
India	O
).	O

The	O
soft	O
gelatin	O
capsule	O
formulation	O
had	O
a	O
label	O
content	O
of	O
1000	O
IU	O
per	O
capsule	O
and	O
the	O
buccal	O
spray	O
formulation	O
had	O
a	O
label	O
content	O
of	O
500	O
IU	O
/	O
spray	O
shot	O
.	O

All	O
participants	O
in	O
group	O
I	O
&	O
III	O
were	O
randomized	O
to	O
receive	O
either	O
the	O
vitamin	O
D3	O
buccal	O
spray	O
(	O
2	O
sprays	O
each	O
of	O
500	O
IU	O
)	O
or	O
soft	O
gelatin	O
capsule	O
containing	O
vitamin	O
D3	O
(	O
1000	O
IU	O
)	O
for	O
30	O
days	O
.	O

Of	O
the	O
fourteen	O
subjects	O
in	O
each	O
group	O
,	O
half	O
received	O
buccal	O
spray	O
and	O
half	O
received	O
soft	O
gelatin	O
capsule	O
.	O

This	O
was	O
considered	O
as	O
period	O
I	O
of	O
the	O
study	O
.	O

After	O
the	O
completion	O
of	O
the	O
30	O
-	O
day	O
treatment	O
,	O
all	O
participants	O
were	O
given	O
a	O
30	O
-	O
day	O
washout	O
.	O

The	O
next	O
treatment	O
in	O
period	O
II	O
was	O
changed	O
in	O
a	O
crossover	O
fashion	O
;	O
those	O
participants	O
who	O
had	O
received	O
the	O
buccal	O
spray	O
formulation	O
(	O
vitamin	O
D3	O
)	O
in	O
period	O
I	O
received	O
the	O
soft	O
gelatin	O
capsule	O
formulation	O
in	O
period	O
II	O
and	O
vice	O
versa	O
.	O

The	O
treatment	O
in	O
period	O
II	O
continued	O
in	O
group	O
I	O
and	O
group	O
III	O
participants	O
for	O
the	O
next	O
30	O
days	O
.	O

The	O
detailed	O
study	O
flow	O
chart	O
is	O
described	O
in	O
Fig	O
.	O
1	O
.	O
Fig	O
.	O
1Study	O
flow	O
chart	O

Compliance	O

All	O
participants	O
were	O
instructed	O
to	O
take	O
the	O
two	O
buccal	O
sprays	O
and	O
one	O
soft	O
gelatin	O
capsule	O
every	O
day	O
irrespective	O
of	O
the	O
period	O
of	O
the	O
study	O
.	O

Formulation	O
for	O
7	O
days	O
was	O
handed	O
over	O
to	O
each	O
participants	O
under	O
group	O
I	O
&	O
III	O
at	O
baseline	O
,	O
along	O
with	O
the	O
compliance	O
form	O
.	O

The	O
participants	O
were	O
instructed	O
to	O
mark	O
the	O
intake	O
and	O
time	O
of	O
intake	O
of	O
number	O
of	O
spray	O
shots	O
or	O
capsule	O
of	O
each	O
day	O
of	O
the	O
study	O
period	O
,	O
as	O
well	O
as	O
to	O
note	O
any	O
extraordinary	O
event	O
that	O
occurred	O
during	O
the	O
period	O
(	O
forgetting	O
to	O
take	O
a	O
spray	O
shot	O
or	O
capsule	O
).	O

If	O
forgetting	O
to	O
take	O
spray	O
shot	O
or	O
capsule	O
,	O
the	O
participants	O
were	O
instructed	O
to	O
take	O
a	O
double	O
dose	O
on	O
the	O
following	O
day	O
,	O
in	O
order	O
to	O
take	O
altogether	O
60	O
spray	O
shots	O
or	O
30	O
capsules	O
during	O
the	O
study	O
periods	O
.	O

The	O
participants	O
were	O
recommended	O
to	O
take	O
spray	O
shots	O
or	O
capsules	O
after	O
the	O
main	O
meal	O
of	O
the	O
day	O
.	O

However	O
,	O
participants	O
were	O
not	O
instructed	O
to	O
standardize	O
meals	O
or	O
time	O
between	O
meals	O
.	O

All	O
participants	O
were	O
also	O
instructed	O
not	O
to	O
change	O
their	O
daily	O
routine	O
,	O
meal	O
habits	O
,	O
as	O
well	O
as	O
their	O
sun	O
exposure	O
.	O

This	O
was	O
done	O
to	O
minimize	O
interference	O
with	O
daily	O
routine	O
and	O
thus	O
maximizing	O
compliance	O
with	O
taking	O
study	O
medication	O
.	O

All	O
participants	O
in	O
group	O
I	O
and	O
III	O
were	O
instructed	O
to	O
visit	O
the	O
site	O
every	O
week	O
to	O
check	O
compliance	O
with	O
the	O
intake	O
of	O
study	O
medication	O
.	O

Participants	O
in	O
control	O
groups	O
(	O
Group	O
II	O
and	O
Group	O
IV	O
)	O
were	O
instructed	O
to	O
visit	O
their	O
respective	O
clinic	O
after	O
30	O
days	O
for	O
their	O
blood	O
sample	O
collection	O
.	O

All	O
participants	O
who	O
received	O
treatment	O
were	O
also	O
instructed	O
to	O
note	O
any	O
adverse	O
events	O
during	O
the	O
entire	O
90	O
days	O
of	O
the	O
study	O
which	O
included	O
period	O
I	O
,	O
washout	O
period	O
and	O
period	O
II	O
in	O
a	O
separately	O
given	O
adverse	O
event	O
recording	O
form	O
.	O

Stastical	O
Analysis	O

Sample	O
size	O

The	O
sample	O
size	O
of	O
this	O
crossover	O
study	O
was	O
based	O
on	O
the	O
changes	O
in	O
25	O
(	O
OH	O
)	O
D	O
levels	O
where	O
goal	O
was	O
to	O
detect	O
:	O
1	O
)	O
percent	O
increase	O
between	O
pre	O
-	O
dose	O
and	O
post	O
-	O
dose	O
levels	O
within	O
treatments	O
,	O
and	O
2	O
)	O
to	O
have	O
significant	O
difference	O
of	O
percent	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
levels	O
between	O
the	O
treatments	O
.	O

To	O
achieve	O
type	O
-	O
I	O
error	O
rate	O
of	O
less	O
than	O
5	O
%	O
(	O
2	O
tailed	O
),	O
a	O
sample	O
size	O
of	O
12	O
subjects	O
in	O
buccal	O
spray	O
group	O
(	O
healthy	O
or	O
patients	O
)	O
was	O
sufficient	O
to	O
provide	O
a	O
statistical	O
power	O
of	O
80	O
%	O
to	O
detect	O
a	O
clinically	O
significant	O
mean	O
difference	O
of	O
5	O
%	O
in	O
25	O
(	O
OH	O
)	O
D	O
levels	O
.	O

Demographic	O
and	O
baseline	O
characteristic	O

A	O
descriptive	O
statistics	O
was	O
applied	O
for	O
demographics	O
;	O
age	O
(	O
years	O
),	O
weight	O
(	O
kg	O
),	O
body	O
mass	O
index	O
(	O
kg	O
/	O
m2	O
);	O
and	O
were	O
presented	O
as	O
mean	O
Â±	O
standard	O
deviation	O
.	O

Efficacy	O
analysis	O

Statistical	O
analyses	O
were	O
performed	O
using	O
GraphPad	O
Prism	O
5	O
,	O
version	O
5	O
.	O
03	O
(	O
GraphPad	O
Software	O
,	O
Inc	O
.,	O
CA	O
,	O
USA	O
).	O

Differences	O
of	O
mean	O
and	O
percentage	O
change	O
from	O
baseline	O
of	O
25	O
(	O
OH	O
)	O
D	O
levels	O
between	O
two	O
formulation	O
groups	O
,	O
soft	O
gelatin	O
capsules	O
and	O
buccal	O
spray	O
,	O
were	O
evaluated	O
using	O
two	O
tailed	O
Paired	O
t	O
-	O
test	O
with	O
95	O
%	O
confidence	O
interval	O
separately	O
for	O
both	O
healthy	O
subjects	O
and	O
patients	O
with	O
intestinal	O
malabsorption	O
.	O

For	O
comparison	O
between	O
control	O
group	O
and	O
either	O
of	O
the	O
treatments	O
,	O
unpaired	O
t	O
-	O
test	O
with	O
95	O
%	O
confidence	O
interval	O
was	O
used	O
.	O

Safety	O
analysis	O

The	O
number	O
and	O
proportion	O
of	O
subjects	O
with	O
changes	O
in	O
laboratory	O
value	O
(	O
change	O
from	O
baseline	O
to	O
end	O
of	O
study	O
visit	O
for	O
complete	O
blood	O
count	O
,	O
serum	O
creatinine	O
,	O
total	O
bilirubin	O
,	O
urea	O
,	O
SGOT	B-GP
,	O
SGPT	B-GP
,	O
alkaline	O
phosphates	O
and	O
calcium	O
)	O
was	O
summarized	O
and	O
the	O
difference	O
was	O
analyzed	O
by	O
chi	O
â€“	O
square	O
test	O
from	O
normal	O
to	O
abnormal	O
.	O

Results	O

Baseline	O
characteristics	O
:	O

In	O
total	O
,	O
thirty	O
eight	O
individuals	O
,	O
thirteen	O
healthy	O
individuals	O
with	O
six	O
control	O
and	O
thirteen	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
with	O
six	O
control	O
,	O
fulfilled	O
the	O
eligibility	O
criteria	O
and	O
completed	O
the	O
study	O
(	O
Fig	O
.	O
1	O
).	O

Two	O
participants	O
(	O
one	O
healthy	O
subject	O
and	O
one	O
patient	O
)	O
reported	O
vitamin	O
D3	O
intake	O
compliance	O
of	O
less	O
than	O
90	O
%	O
and	O
therefore	O
were	O
not	O
considered	O
for	O
final	O
analyses	O
.	O

In	O
healthy	O
subjects	O
,	O
at	O
baseline	O
,	O
85	O
%	O
(	O
n	O
=	O
12	O
)	O
of	O
the	O
subjects	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
,	O
and	O
one	O
individual	O
each	O
(	O
7	O
.	O
14	O
%)	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
>	O
30	O
ng	O
/	O
ml	O
and	O
<	O
10	O
ng	O
/	O
ml	O
each	O
in	O
the	O
oral	O
soft	O
gelatin	O
capsule	O
group	O
.	O

While	O
in	O
the	O
buccal	O
spray	O
group	O
,	O
at	O
baseline	O
all	O
subjects	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
.	O

Similarly	O
,	O
in	O
patients	O
with	O
malabsorption	B-DS
disease	I-DS
who	O
received	O
oral	O
soft	O
gelatin	O
capsules	O
,	O
at	O
baseline	O
8	O
(	O
57	O
.	O
14	O
%)	O
patients	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
below	O
10	O
ng	O
/	O
ml	O
,	O
5	O
(	O
35	O
.	O
71	O
%)	O
patients	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
20	O
ng	O
/	O
ml	O
,	O
and	O
one	O
individual	O
(	O
7	O
.	O
14	O
%)	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
above	O
20	O
ng	O
/	O
ml	O
.	O

However	O
,	O
in	O
the	O
buccal	O
spray	O
group	O
,	O
at	O
baseline	O
9	O
(	O
64	O
.	O
28	O
%)	O
patients	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
below	O
10	O
ng	O
/	O
ml	O
and	O
5	O
(	O
35	O
.	O
71	O
%)	O
patients	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
20	O
ng	O
/	O
ml	O
.	O

There	O
were	O
no	O
striking	O
differences	O
in	O
baseline	O
characteristics	O
between	O
healthy	O
individuals	O
or	O
patients	O
with	O
malabsorption	B-DS
disease	I-DS
with	O
their	O
corresponding	O
control	O
groups	O
(	O
Table	O
1	O
).	O
Table	O
1Demographic	O
Data	O
for	O
Healthy	O
Subjects	O
and	O
Patients	O
with	O
malabsorption	O
syndromeParametersHealthy	O
Subjects	O
Group	O
IHealthy	O
Subjects	O
Control	O
Group	O
IIPatients	O
with	O
malabsorption	B-DS
syndrome	I-DS
Group	O
IIIPatients	O
with	O
malabsorption	O
syndromeControlGroup	O
IVN146146SexMale	O
=	O
7	O
,	O
Female	O
=	O
7Male	O
=	O
3	O
,	O
Female	O
=	O
3Male	O
=	O
7	O
,	O
Female	O
=	O
7Male	O
=	O
3	O
,	O
Female	O
=	O
3Age	O
(	O
Yrs	O
)	O
36	O
.	O
21	O
Â±	O
9	O
.	O
9734	O
.	O
00	O
Â±	O
6	O
.	O
4239	O
.	O
93	O
Â±	O
11	O
.	O
6544	O
.	O
17	O
Â±	O
5	O
.	O
56	O
(	O
Range	O
)(	O
25	O
â€“	O
60	O
)(	O
25	O
â€“	O
42	O
)(	O
26	O
â€“	O
63	O
)(	O
38	O
â€“	O
53	O
)	O
Height	O
(	O
cms	O
)	O
159	O
.	O
86	O
Â±	O
13	O
.	O
43161	O
.	O
33	O
Â±	O
14	O
.	O
12162	O
.	O
29	O
Â±	O
8	O
.	O
54164	O
.	O
33	O
Â±	O
8	O
.	O
55BMI23	O
.	O
39	O
Â±	O
3	O
.	O
8821	O
.	O
40	O
Â±	O
2	O
.	O
3921	O
.	O
48	O
Â±	O
2	O
.	O
8223	O
.	O
64	O
Â±	O
3	O
.	O
02All	O
values	O
are	O
expressed	O
in	O
Mean	O
Â±	O
SD	O
;	O
N	O
-	O
number	O
subjects	O
in	O
each	O
group	O

Effect	O
of	O
intervention	O

The	O
control	O
groups	O
in	O
each	O
subject	O
population	O
were	O
compared	O
with	O
their	O
corresponding	O
treatment	O
group	O
.	O

The	O
control	O
groups	O
for	O
healthy	O
subjects	O
as	O
well	O
as	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
showed	O
no	O
change	O
in	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
over	O
a	O
period	O
of	O
30	O
days	O
.	O

The	O
mean	O
baseline	O
levels	O
of	O
25	O
(	O
OH	O
)	O
D	O
in	O
healthy	O
subjects	O
was	O
18	O
.	O
25	O
ng	O
/	O
ml	O
and	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
was	O
11	O
.	O
7	O
ng	O
/	O
ml	O
.	O

These	O
mean	O
levels	O
remained	O
at	O
18	O
.	O
06	O
ng	O
/	O
ml	O
and	O
12	O
.	O
52	O
ng	O
/	O
ml	O
after	O
30	O
days	O
in	O
healthy	O
subjects	O
and	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
respectively	O
(	O
Fig	O
.	O
2	O
),	O
which	O
was	O
statistically	O
non	O
-	O
significant	O
.	O

When	O
control	O
group	O
in	O
healthy	O
subjects	O
was	O
compared	O
with	O
their	O
corresponding	O
treatment	O
groups	O
,	O
it	O
was	O
found	O
that	O
the	O
difference	O
of	O
mean	O
between	O
control	O
group	O
and	O
buccal	O
spray	O
group	O
was	O
7	O
.	O
47	O
(	O
95	O
%	O
CI	O
,	O
5	O
.	O
27	O
,	O
9	O
.	O
67	O
)	O
which	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
and	O
the	O
same	O
between	O
control	O
group	O
and	O
soft	O
gelatin	O
capsule	O
group	O
was	O
3	O
.	O
53	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
79	O
,	O
5	O
.	O
28	O
)	O
which	O
was	O
also	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
).	O

Similarly	O
in	O
patients	O
,	O
the	O
difference	O
of	O
mean	O
between	O
control	O
group	O
and	O
buccal	O
spray	O
group	O
was	O
8	O
.	O
53	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
74	O
,	O
14	O
.	O
31	O
)	O
which	O
was	O
significant	O
(	O
p	O
<	O
0	O
.	O
05	O
),	O
while	O
the	O
difference	O
of	O
mean	O
between	O
control	O
group	O
and	O
soft	O
gelatin	O
capsule	O
group	O
was	O
2	O
.	O
03	O
(	O
95	O
%	O
CI	O
,	O
âˆ’	O
1	O
.	O
44	O
,	O
5	O
.	O
50	O
)	O
which	O
was	O
statistically	O
not	O
significant	O
.	O

This	O
shows	O
that	O
buccal	O
spray	O
was	O
more	O
effective	O
to	O
increase	O
mean	O
25	O
(	O
OH	O
)	O
D	O
levels	O
as	O
compared	O
to	O
oral	O
soft	O
gelatin	O
capsule	O
.	O

Table	O
2	O
describes	O
these	O
data	O
.	O
Fig	O
.	O
2Mean	O
25	O
(	O
OH	O
)	O
D	O
level	O
in	O
study	O
subjectsTable	O
2Comparison	O
of	O
25	O
(	O
OH	O
)	O
D	O
in	O
control	O
group	O
and	O
their	O
corresponding	O
treatment	O
groups	O
after	O
30	O
daysComparisonDifference	O
of	O
mean95	O
%	O
CIP	O
ValueHealthy	O
â€“	O
Buccal	O
Spray	O
vs	O
.	O
Control7	O
.	O
475	O
.	O
27	O
to	O
9	O
.	O
67	O
<	O
0	O
.	O
0001Healthy	O
â€“	O
Soft	O
Gelatin	O
Capsule	O
vs	O
.	O
Control3	O
.	O
531	O
.	O
79	O
to	O
5	O
.	O
280	O
.	O
0005Patients	O
â€“	O
Buccal	O
Spray	O
vs	O
.	O
Control8	O
.	O
532	O
.	O
74	O
to	O
14	O
.	O
310	O
.	O
0064Patients	O
â€“	O
Soft	O
Gelatin	O
Capsule	O
vs	O
.	O
Control2	O
.	O
03	O
âˆ’	O
1	O
.	O
44	O
to	O
5	O
.	O
500	O
.	O
2338	O

The	O
efficacy	O
of	O
buccal	O
spray	O
and	O
soft	O
gelatin	O
capsule	O
to	O
increase	O
the	O
25	O
(	O
OH	O
)	O
D	O
levels	O
after	O
30	O
days	O
of	O
administration	O
was	O
evaluated	O
and	O
compared	O
with	O
each	O
other	O
.	O

After	O
30	O
days	O
of	O
administration	O
,	O
overall	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
in	O
healthy	O
subjects	O
was	O
22	O
.	O
75	O
(	O
sd	O
6	O
.	O
75	O
)	O
ng	O
/	O
ml	O
as	O
compared	O
to	O
baseline	O
value	O
of	O
18	O
.	O
69	O
(	O
sd	O
5	O
.	O
88	O
)	O
ng	O
/	O
ml	O
in	O
the	O
soft	O
gelatin	O
capsule	O
group	O
,	O
with	O
the	O
mean	O
increase	O
of	O
4	O
.	O
06	O
(	O
95	O
%	O
CI	O
3	O
.	O
41	O
,	O
4	O
.	O
71	O
)	O
ng	O
/	O
ml	O
(	O
Table	O
3	O
).	O

On	O
the	O
other	O
hand	O
,	O
in	O
the	O
buccal	O
spray	O
group	O
,	O
the	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
26	O
.	O
91	O
(	O
sd	O
5	O
.	O
72	O
)	O
ng	O
/	O
ml	O
as	O
compared	O
to	O
baseline	O
value	O
of	O
18	O
.	O
91	O
(	O
sd	O
4	O
.	O
3	O
)	O
ng	O
/	O
ml	O
,	O
with	O
the	O
mean	O
increase	O
of	O
8	O
.	O
0	O
(	O
95	O
%	O
CI	O
6	O
.	O
86	O
,	O
9	O
.	O
13	O
)	O
ng	O
/	O
ml	O
(	O
Fig	O
.	O
2	O
).	O

The	O
difference	O
in	O
mean	O
increase	O
between	O
both	O
the	O
groups	O
was	O
3	O
.	O
95	O
(	O
95	O
%	O
CI	O
3	O
.	O
19	O
,	O
4	O
.	O
69	O
)	O
which	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O
Table	O
3Level	O
of	O
25	O
(	O
OH	O
)	O
D	O
in	O
Healthy	O
Subjects	O
and	O
Patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
after	O
30	O
day	O
administration	O
of	O
vitamin	O
D3	O
buccal	O
spray	O
and	O
soft	O
gelatin	O
capsuleParametersMean	O
baseline	O
value	O
in	O
ng	O
/	O
mlMean	O
value	O
in	O
ng	O
/	O
ml	O
after	O
30	O
day	O
of	O
treatmentDifference	O
of	O
meanPercentage	O
mean	O
increase	O
from	O
baselineHealthy	O
SubjectsSoft	O
gelatin	O
Capsule	O
Formulation	O
Mean18	O
.	O
69	O
Â±	O
5	O
.	O
8822	O
.	O
75	O
Â±	O
6	O
.	O
754	O
.	O
0621	O
.	O
72	O
%	O
Range9	O
.	O
25	O
,	O
30	O
.	O
0512	O
.	O
75	O
,	O
35	O
.	O
522	O
.	O
5	O
,	O
5	O
.	O
615	O
.	O
36	O
,	O
37	O
.	O
79	O
n13131313	O
95	O
%	O
CI15	O
.	O
14	O
to	O
22	O
.	O
2418	O
.	O
67	O
to	O
24	O
.	O
423	O
.	O
41	O
to	O
4	O
.	O
7116	O
.	O
42	O
to	O
24	O
.	O
42Buccal	O
Spray	O
Formulation	O
Mean18	O
.	O
91	O
Â±	O
4	O
.	O
326	O
.	O
91	O
Â±	O
5	O
.	O
727	O
.	O
99542	O
.	O
99	O
%	O
Range13	O
.	O
36	O
,	O
26	O
.	O
8219	O
.	O
6	O
,	O
38	O
.	O
54	O
.	O
5	O
,	O
11	O
.	O
6729	O
.	O
21	O
,	O
68	O
.	O
71	O
n13131313	O
95	O
%	O
CI16	O
.	O
31	O
to	O
21	O
.	O
5123	O
.	O
45	O
to	O
30	O
.	O
366	O
.	O
86	O
to	O
9	O
.	O
1337	O
.	O
19	O
to	O
48	O
.	O
79Patients	O
with	O
intestinal	O
malabsorption	O
syndromeSoft	O
gelatin	O
Capsule	O
Formulation	O
Mean11	O
.	O
01	O
Â±	O
6	O
.	O
4314	O
.	O
97	O
Â±	O
9	O
.	O
013	O
.	O
96536	O
.	O
02	O
%	O
Range2	O
.	O
9	O
,	O
26	O
.	O
54	O
.	O
6	O
,	O
36	O
.	O
891	O
.	O
06	O
,	O
10	O
.	O
3924	O
.	O
62	O
,	O
58	O
.	O
73	O
n13131313	O
95	O
%	O
CI7	O
.	O
12	O
to	O
14	O
.	O
899	O
.	O
52	O
to	O
20	O
.	O
422	O
.	O
37	O
to	O
5	O
.	O
5630	O
.	O
42	O
to	O
41	O
.	O
62Buccal	O
Spray	O
Formulation	O
Mean10	O
.	O
01	O
Â±	O
4	O
.	O
2920	O
.	O
47	O
Â±	O
7	O
.	O
8910	O
.	O
46117	O
.	O
8	O
%	O
Range4	O
.	O
6	O
,	O
18	O
.	O
859	O
.	O
8	O
,	O
34	O
.	O
644	O
.	O
25	O
,	O
27	O
.	O
4461	O
.	O
31	O
,	O
381	O
.	O
1	O
n13131313	O
95	O
%	O
CI7	O
.	O
42	O
to	O
12	O
.	O
615	O
.	O
7	O
to	O
25	O
.	O
246	O
.	O
89	O
to	O
14	O
.	O
0364	O
.	O
71	O
to	O
170	O
.	O
8	O

When	O
calculated	O
from	O
baseline	O
,	O
the	O
mean	O
percentage	O
change	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
in	O
healthy	O
subjects	O
after	O
30	O
days	O
treatment	O
with	O
soft	O
gelatin	O
capsule	O
was	O
21	O
.	O
72	O
%	O
(	O
95	O
%	O
CI	O
16	O
.	O
42	O
,	O
24	O
.	O
42	O
),	O
while	O
the	O
same	O
in	O
buccal	O
spray	O
group	O
was	O
42	O
.	O
99	O
%	O
(	O
95	O
%	O
CI	O
37	O
.	O
19	O
,	O
48	O
.	O
79	O
)	O
with	O
a	O
mean	O
difference	O
of	O
20	O
.	O
42	O
%	O
(	O
95	O
%	O
CI	O
16	O
.	O
42	O
,	O
24	O
.	O
42	O
)	O
between	O
two	O
groups	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
(	O
Table	O
3	O
).	O

A	O
total	O
of	O
11	O
(	O
85	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
,	O
and	O
two	O
individuals	O
(	O
15	O
.	O
38	O
%)	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
>	O
30	O
ng	O
/	O
ml	O
in	O
the	O
soft	O
gelatin	O
capsule	O
group	O
.	O

However	O
,	O
in	O
the	O
buccal	O
spray	O
group	O
,	O
10	O
(	O
75	O
.	O
88	O
%)	O
subjects	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
and	O
3	O
(	O
23	O
.	O
1	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
>	O
30	O
ng	O
/	O
ml	O
.	O

Similarly	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
,	O
overall	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
after	O
30	O
days	O
of	O
administration	O
of	O
soft	O
gelatin	O
capsule	O
was	O
14	O
.	O
97	O
(	O
sd	O
9	O
.	O
01	O
)	O
ng	O
/	O
ml	O
as	O
compared	O
to	O
baseline	O
value	O
of	O
11	O
.	O
01	O
(	O
sd	O
6	O
.	O
43	O
)	O
ng	O
/	O
ml	O
,	O
with	O
the	O
mean	O
increase	O
of	O
3	O
.	O
96	O
(	O
95	O
%	O
CI	O
2	O
.	O
37	O
,	O
5	O
.	O
56	O
)	O
ng	O
/	O
ml	O
.	O

While	O
in	O
buccal	O
spray	O
group	O
,	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
was	O
20	O
.	O
47	O
(	O
sd	O
7	O
.	O
89	O
)	O
ng	O
/	O
ml	O
as	O
compared	O
to	O
baseline	O
value	O
of	O
10	O
.	O
01	O
(	O
sd	O
4	O
.	O
29	O
)	O
ng	O
/	O
ml	O
,	O
with	O
the	O
mean	O
increase	O
of	O
10	O
.	O
46	O
(	O
95	O
%	O
CI	O
6	O
.	O
89	O
,	O
14	O
.	O
03	O
)	O
ng	O
/	O
ml	O
(	O
Fig	O
.	O
2	O
).	O

The	O
difference	O
in	O
mean	O
increase	O
between	O
both	O
the	O
groups	O
was	O
6	O
.	O
50	O
(	O
95	O
%	O
CI	O
3	O
.	O
78	O
,	O
9	O
.	O
22	O
)	O
which	O
was	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
0001	O
).	O

The	O
mean	O
percentage	O
change	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
after	O
30	O
days	O
treatment	O
with	O
soft	O
gelatin	O
capsule	O
was	O
36	O
.	O
02	O
%	O
(	O
95	O
%	O
CI	O
30	O
.	O
42	O
,	O
41	O
.	O
62	O
),	O
while	O
the	O
same	O
value	O
in	O
buccal	O
spray	O
group	O
was	O
117	O
.	O
8	O
%	O
(	O
95	O
%	O
CI	O
64	O
.	O
71	O
,	O
170	O
.	O
8	O
)	O
with	O
a	O
mean	O
difference	O
of	O
81	O
.	O
75	O
%	O
(	O
95	O
%	O
CI	O
29	O
.	O
80	O
,	O
133	O
.	O
7	O
)	O
between	O
the	O
two	O
treatments	O
(	O
p	O
<	O
0	O
.	O
005	O
).	O

A	O
total	O
of	O
four	O
(	O
31	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
below	O
10	O
ng	O
/	O
ml	O
,	O
eight	O
(	O
61	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
,	O
and	O
one	O
individual	O
(	O
7	O
.	O
7	O
%)	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
above	O
30	O
ng	O
/	O
ml	O
.	O

However	O
,	O
in	O
the	O
buccal	O
spray	O
group	O
,	O
only	O
7	O
.	O
7	O
%	O
(	O
1	O
subject	O
)	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
below	O
10	O
ng	O
/	O
ml	O
,	O
ten	O
(	O
76	O
.	O
9	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
between	O
10	O
and	O
30	O
ng	O
/	O
ml	O
and	O
two	O
(	O
15	O
.	O
4	O
%)	O
subjects	O
now	O
had	O
serum	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
more	O
than	O
30	O
ng	O
/	O
ml	O
(	O
Table	O
3	O
).	O

Statistical	O
considerations	O
with	O
respect	O
to	O
period	O
,	O
sequence	O
and	O
power	O
:	O

Statistical	O
analyses	O
were	O
performed	O
using	O
SAS	O
v9	O
.	O
2	O
(	O
SAS	O
Institute	O
Inc	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
for	O
the	O
post	O
-	O
hoc	O
evaluation	O
of	O
sequence	O
and	O
period	O
effect	O
.	O

The	O
statistical	O
method	O
adopted	O
for	O
this	O
analysis	O
was	O
period	O
+	O
sequence	O
+	O
Subject	O
(	O
sequence	O
)	O
+	O
treatment	O
.	O

It	O
was	O
observed	O
that	O
there	O
is	O
no	O
significant	O
difference	O
in	O
sequence	O
effect	O
in	O
healthy	O
subjects	O
(	O
p	O
=	O
0	O
.	O
5251	O
)	O
and	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
(	O
p	O
=	O
0	O
.	O
0532	O
).	O

It	O
was	O
also	O
revealed	O
that	O
there	O
is	O
no	O
statistically	O
significant	O
period	O
effect	O
in	O
healthy	O
subjects	O
(	O
p	O
=	O
0	O
.	O
6920	O
)	O
as	O
well	O
as	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
(	O
p	O
=	O
0	O
.	O
0715	O
).	O

The	O
post	O
-	O
hoc	O
power	O
analyses	O
with	O
intra	O
-	O
subject	O
variability	O
were	O
also	O
derived	O
for	O
both	O
the	O
group	O
of	O
subjects	O
.	O

In	O
healthy	O
subjects	O
,	O
statistical	O
power	O
obtained	O
was	O
99	O
.	O
42	O
with	O
an	O
11	O
.	O
81	O
%	O
intra	O
-	O
subject	O
variability	O
.	O

While	O
,	O
in	O
patients	O
with	O
malabsorption	B-DS
syndrome	I-DS
it	O
was	O
81	O
.	O
62	O
with	O
an	O
intra	O
-	O
subject	O
variability	O
of	O
21	O
.	O
86	O
%.	O

Safety	O
evaluation	O

There	O
were	O
no	O
significant	O
changes	O
in	O
any	O
of	O
the	O
hematology	O
and	O
biochemistry	O
parameters	O
studied	O
.	O

There	O
are	O
also	O
no	O
notable	O
changes	O
in	O
the	O
vitals	O
for	O
any	O
of	O
the	O
participants	O
.	O

No	O
adverse	O
event	O
reported	O
after	O
administration	O
of	O
the	O
buccal	O
spray	O
or	O
soft	O
gelatin	O
capsule	O
formulations	O
of	O
vitamin	O
D3	O
during	O
entire	O
study	O
period	O
in	O
healthy	O
or	O
patients	O
with	O
malabsorption	B-DS
disease	I-DS
and	O
hence	O
the	O
product	O
is	O
considered	O
safe	O
.	O

Discussion	O

Supplemental	O
fat	O
-	O
soluble	O
vitamin	O
D	O
is	O
usually	O
made	O
without	O
determination	O
of	O
whether	O
oral	O
doses	O
are	O
adequately	O
absorbed	O
.	O

The	O
evidence	O
of	O
vitamin	O
D	O
malabsorption	O
(	O
Osteomalacia	B-DS
,	O
rickets	B-DS
,	O
hypocalcaemia	B-DS
,	O
or	O
reduced	O
circulating	O
concentration	O
of	O
25	O
(	O
OH	O
)	O
D	O
)	O
persists	O
despite	O
routine	O
vitamin	O
D	O
supplementation	O
in	O
cystic	B-DS
fibrosis	I-DS
[	O
14	O
],	O
Crohn	B-DS
â€™	I-DS
s	I-DS
disease	I-DS
[	O
15	O
],	O
Intestinal	O
resection	O
[	O
16	O
â€“	O
19	O
],	O
ulcerative	B-DS
colitis	I-DS
,	O
liver	B-DS
disease	I-DS
[	O
20	O
â€“	O
22	O
]	O
and	O
other	O
malabsorption	B-DS
syndrome	I-DS
[	O
23	O
].	O

Many	O
factors	O
are	O
involved	O
in	O
the	O
absorption	O
of	O
vitamin	O
D	O
,	O
including	O
gastric	O
,	O
pancreatic	O
,	O
and	O
biliary	O
secretions	O
,	O
micelle	O
formation	O
,	O
and	O
diffusion	O
through	O
the	O
unstirred	O
water	O
layer	O
,	O
brush	O
border	O
membrane	O
uptake	O
,	O
and	O
transport	O
out	O
of	O
the	O
intestinal	O
cell	O
[	O
24	O
,	O
25	O
].	O

As	O
vitamin	O
D	O
is	O
a	O
relatively	O
non	O
-	O
polar	O
sterol	O
,	O
it	O
must	O
be	O
solubilized	O
by	O
incorporation	O
into	O
a	O
bile	O
salt	O
micelle	O
solution	O
in	O
order	O
to	O
be	O
absorbed	O
in	O
the	O
aqueous	O
phase	O
[	O
26	O
].	O

This	O
process	O
is	O
severely	O
inhibited	O
if	O
there	O
is	O
any	O
interruption	O
of	O
normal	O
pancreatic	O
or	O
biliary	O
secretion	O
.	O

As	O
fat	O
-	O
soluble	O
vitamins	O
are	O
fairly	O
sensitive	O
to	O
disturbances	O
in	O
lipid	O
absorption	O
,	O
vitamin	O
malabsorption	O
may	O
occur	O
in	O
conditions	O
like	O
steatorrhea	O
,	O
ulcerative	B-DS
colitis	I-DS
,	O
and	O
Crohn	B-DS
â€™	I-DS
s	I-DS
disease	I-DS
.	O

Serum	O
concentrations	O
of	O
25	O
-	O
hydroxyvitamin	O
D	O
are	O
good	O
indicators	O
of	O
long	O
term	O
vitamin	O
D	O
levels	O
in	O
the	O
body	O
but	O
are	O
insensitive	O
to	O
single	O
doses	O
of	O
vitamin	O
D	O
and	O
do	O
not	O
rise	O
out	O
of	O
the	O
normal	O
range	O
unless	O
doses	O
of	O
vitamin	O
D	O
are	O
chronically	O
administered	O
[	O
27	O
].	O

Considering	O
the	O
malabsorption	O
in	O
intestinal	B-DS
disease	I-DS
and	O
a	O
possible	O
poor	O
and	O
complex	O
absorption	O
with	O
oral	O
formulations	O
,	O
a	O
novel	O
nanoemulsion	O
formulation	O
of	O
buccal	O
spray	O
was	O
developed	O
where	O
vitamin	O
D3	O
is	O
suspended	O
in	O
an	O
aqueous	O
base	O
which	O
can	O
be	O
easily	O
absorbed	O
through	O
the	O
mucosal	O
layer	O
of	O
the	O
mouth	O
.	O

We	O
compared	O
the	O
serum	O
concentration	O
of	O
vitamin	O
D	O
after	O
30	O
days	O
administration	O
with	O
the	O
soft	O
gelatin	O
capsule	O
and	O
the	O
aqueous	O
based	O
buccal	O
spray	O
formulation	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
randomized	O
two	O
way	O
cross	O
over	O
trial	O
comparing	O
the	O
increase	O
in	O
25	O
(	O
OH	O
)	O
D	O
levels	O
in	O
healthy	O
adults	O
and	O
patients	O
with	O
intestinal	O
malabsorption	O
receiving	O
similar	O
oral	O
doses	O
of	O
two	O
different	O
formulations	O
(	O
per	O
oral	O
and	O
buccal	O
spray	O
).	O

The	O
analyses	O
of	O
baseline	O
levels	O
of	O
study	O
participants	O
showed	O
that	O
vitamin	B-DS
D	I-DS
deficiency	I-DS
was	O
prevalent	O
in	O
both	O
healthy	O
subjects	O
and	O
patients	O
with	O
intestinal	B-DS
malabsorption	I-DS
syndrome	I-DS
.	O

However	O
,	O
patients	O
were	O
more	O
vitamin	O
D	O
deficient	O
as	O
compared	O
to	O
healthy	O
subjects	O
.	O

Four	O
weeks	O
administration	O
of	O
1000	O
IU	O
per	O
day	O
increased	O
mean	O
serum	O
25	O
(	O
OH	O
)	O
D	O
in	O
all	O
treatment	O
groups	O
.	O

In	O
healthy	O
subjects	O
,	O
soft	O
gelatin	O
capsule	O
increased	O
serum	O
25	O
(	O
OH	O
)	O
D	O
level	O
by	O
22	O
.	O
5	O
%	O
(	O
Range	O
15	O
.	O
4	O
to	O
37	O
.	O
8	O
%),	O
while	O
the	O
buccal	O
spray	O
increased	O
serum	O
25	O
(	O
OH	O
)	O
D	O
level	O
by	O
43	O
%	O
(	O
range	O
29	O
.	O
2	O
to	O
68	O
.	O
7	O
.	O

Similarly	O
,	O
in	O
patients	O
with	O
intestinal	O
malabsorption	O
,	O
soft	O
gelatin	O
capsule	O
increased	O
serum	O
25	O
(	O
OH	O
)	O
D	O
level	O
by	O
36	O
%	O
(	O
range	O
24	O
.	O
6	O
to	O
58	O
.	O
7	O
%)	O
and	O
the	O
buccal	O
spray	O
increased	O
serum	O
25	O
(	O
OH	O
)	O
D	O
by	O
117	O
.	O
8	O
%	O
(	O
range	O
61	O
.	O
3	O
to	O
381	O
.	O
1	O
%).	O

The	O
result	O
implies	O
that	O
the	O
buccal	O
spray	O
formulation	O
had	O
a	O
significantly	O
higher	O
mean	O
increase	O
in	O
both	O
the	O
subject	O
groups	O
,	O
healthy	O
subjects	O
and	O
patients	O
with	O
intestinal	B-DS
malabsorption	I-DS
syndrome	I-DS
.	O

Interestingly	O
,	O
the	O
mean	O
increase	O
was	O
much	O
higher	O
in	O
the	O
patients	O
group	O
as	O
compared	O
to	O
the	O
healthy	O
subjects	O
group	O
.	O

This	O
may	O
be	O
because	O
increase	O
in	O
serum	O
25	O
(	O
OH	O
)	O
D	O
after	O
supplementation	O
is	O
known	O
to	O
be	O
inversely	O
related	O
to	O
baseline	O
25	O
(	O
OH	O
)	O
D	O
concentration	O
[	O
28	O
].	O

In	O
the	O
present	O
study	O
,	O
the	O
mean	O
baseline	O
levels	O
were	O
almost	O
half	O
in	O
patients	O
with	O
intestinal	O
malabsorption	O
as	O
compared	O
to	O
the	O
baseline	O
levels	O
found	O
in	O
healthy	O
subjects	O
.	O

This	O
indicates	O
the	O
presence	O
of	O
vitamin	B-DS
D3	I-DS
deficiency	I-DS
in	O
the	O
patient	O
group	O
as	O
compared	O
to	O
healthy	O
subjects	O
.	O

The	O
primary	O
and	O
the	O
most	O
important	O
source	O
of	O
vitamin	O
D	O
is	O
sunlight	O
.	O

Although	O
excessive	O
exposure	O
to	O
sunlight	O
and	O
vitamin	O
D	O
have	O
been	O
positively	O
associated	O
with	O
non	B-DS
-	I-DS
melanoma	I-DS
skin	I-DS
cancer	I-DS
[	O
29	O
],	O
ecological	O
studies	O
suggest	O
that	O
sunlight	O
may	O
protect	O
against	O
female	O
breast	O
,	O
ovarian	O
,	O
prostate	O
,	O
and	O
colon	B-DS
cancer	I-DS
[	O
30	O
].	O

Solar	O
UV	O
-	O
B	O
exposure	O
and	O
the	O
amount	O
of	O
exposure	O
to	O
sun	O
are	O
related	O
inversely	O
with	O
cancer	B-DS
mortality	O
and	O
survival	O
in	O
detailed	O
epidemiological	O
studies	O
[	O
31	O
].	O

Some	O
analytical	O
studies	O
suggest	O
a	O
protective	O
association	O
between	O
circulating	O
vitamin	O
D	O
in	O
blood	O
,	O
which	O
is	O
largely	O
derived	O
from	O
sunlight	O
or	O
dietary	O
vitamin	O
D	O
,	O
and	O
colorectal	B-DS
cancer	I-DS
and	O
prostate	B-DS
cancer	I-DS
[	O
30	O
].	O

However	O
,	O
looking	O
at	O
the	O
overall	O
baseline	O
levels	O
of	O
all	O
participants	O
in	O
the	O
present	O
study	O
,	O
it	O
is	O
also	O
advisable	O
to	O
increase	O
the	O
moderate	O
daily	O
sun	O
exposure	O
and	O
to	O
improve	O
clothing	O
apart	O
from	O
vitamin	O
D3	O
supplementation	O
.	O

Conclusion	O

We	O
conclude	O
that	O
the	O
buccal	O
spray	O
formulation	O
was	O
able	O
to	O
increase	O
mean	O
serum	O
vitamin	O
D3	O
concentration	O
significantly	O
higher	O
as	O
compared	O
to	O
the	O
soft	O
gelatin	O
capsule	O
,	O
in	O
both	O
healthy	O
subjects	O
(	O
1	O
.	O
9	O
times	O
)	O
as	O
well	O
as	O
in	O
patients	O
with	O
intestinal	B-DS
malabsorption	I-DS
syndrome	I-DS
(	O
2	O
.	O
6	O
times	O
).	O

Availability	O
of	O
supporting	O
data	O

The	O
data	O
set	O
(	O
s	O
)	O
supporting	O
the	O
results	O
of	O
this	O
article	O
is	O
(	O
are	O
)	O
included	O
within	O
the	O
article	O
.	O

Competing	O
interests	O

The	O
author	O
(	O
s	O
)	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Authors	O
'	O
contributions	O

MCS	O
participated	O
in	O
design	O
of	O
the	O
study	O
,	O
analyses	O
and	O
interpretation	O
of	O
data	O
,	O
performed	O
the	O
statistical	O
analyses	O
,	O
and	O
drafting	O
revising	O
,	O
and	O
finalizing	O
the	O
manuscript	O
.	O

AGM	O
participated	O
as	O
investigator	O
in	O
the	O
study	O
,	O
involved	O
in	O
healthy	O
subject	O
recruitment	O
,	O
their	O
compliance	O
and	O
acquisition	O
of	O
the	O
data	O
.	O

KDT	O
participated	O
as	O
investigator	O
in	O
the	O
study	O
,	O
involved	O
in	O
patient	O
recruitment	O
,	O
their	O
compliance	O
and	O
acquisition	O
of	O
the	O
data	O
.	O

MSB	O
participated	O
as	O
investigator	O
in	O
the	O
study	O
,	O
involved	O
in	O
patient	O
recruitment	O
,	O
their	O
compliance	O
and	O
acquisition	O
of	O
the	O
data	O
.	O

All	O
authors	O
have	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

